[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ras-mutated-metastatic-colorectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ras-mutated-metastatic-colorectal-cancer":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627260",false,"NCT07446322","FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer","An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer","Inclusion Criteria:\n\n* Histologically confirmed cancer of the colon or rectum with documented metastasis\n* Measurable disease per RECIST v. 1.1\n* Not candidates for curative surgery or curative radiation\n* Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin\n* Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab\n* Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H\u002Fnon dMMR) tumor status per a standard local testing method\n* Tumor confirmed to harbor a known RAS mutation per a standard local testing method\n* ECOG performance status of 0 or 1\n* Patients must have adequate hematological, renal, and hepatic function\n* Female patients of childbearing potential must have a negative pregnancy test\n* Life expectancy of at least 6 months\n\nExclusion Criteria:\n\n* Undergone systemic chemotherapy, radiotherapy, or surgery, \\\u003C4 weeks before study treatment\n* Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment\n* Prior treatment with irinotecan\n* Symptomatic brain metastases\n* Active autoimmune disease\n* Receiving immunosuppressive or myelosuppressive medications\n* Active, uncontrolled infections\n* Known HIV infection or active hepatitis B or C that requires anti-viral treatment\n* History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ\n* History of allergy or known hypersensitivity to any of the study drugs, study drug classes,\n* Uncontrolled or severe cardiac disease\n* Received any vaccine within 28 days prior to first study treatment","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.",[25,26,27],"Ras-mutated Metastatic Colorectal Cancer","mCRC","MSS Metastatic Colorectal Cancer","RECRUITING","2026-06-04",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":32},"2026-04-30",{"date":36,"type":19},"2030-04-30",{"name":38,"class":39},"Oncolytics Biotech","INDUSTRY",3,""]